ClinicalTrials.gg

Program

PRAME mRNA Vaccine mRNA-4203

Its studies are mostly in Melanoma, led by Immatics US.

Furthest: phase 1, since Apr 19, 20251 company-led study, 1 open or runningNext primary completion: Aug 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immatics US11 open or runningphase 1since Apr 19, 2025Apr 19, 2025Aug 2029phase 1 · NCT06946225

Also a collaborator on its studies: Moderna.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2025First study: phase 1 study in MelanomaFirst studyNCT06946225 · 15 planned · United States

Ahead

  1. Aug 2029Primary completion: phase 1 study in MelanomaNCT06946225

TargetBeta

PRAME →read by rule
“A cancer vaccine consisting of a lipid nanoparticle (LNP) encapsulating messenger RNA (mRNA) encoding for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule

Other programs on PRAME

ProgramCompanyFurthest phaseStudies
anzutresgene autoleucelruleImmatics USphase 33
Autologous Anti-PRAME TCR-expressing T-cells OPB-201ruleoutpace-bio-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06946225Melanoma · United States1RecruitingAug 202915

How it is read

Names in the registry

  • “mRNA-4203”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.